LY364947
(Synonyms: HTS466284) 目录号 : GC11604
LY364947是一种强效的ATP竞争性TGFβR-I抑制剂，其IC50为59nM。
Cas No.:396129-53-6
Sample solution is provided at 25 µL, 10mM.
LY364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59nM[1]. TGFβRI is a serine/threonine kinase type I receptor of the TGF-β pathway that, upon activation, phosphorylates Smad2/3 to mediate fibrosis, immune suppression, and tumor progression[2]. LY364947 is widely used in research of TGF-β-related fibrosis, cancer, and immune-modulation by blocking the TGF-β/Smad signaling cascade[3][4].
In vitro, treatment of human dermal lymphatic microvascular endothelial cells (HDLECs) with LY364947 (3μM; 24h) significantly induces the expression of Prox1 and LYVE-1 and inhibits TGF-β1-induced Smad2 phosphorylation, while promoting cord formation and cell migration[5]. Treatment of CML leukemia-initiating cells (LICs) with LY364947 (10µM; 2h) increased the nuclear export of Foxo3a, decreased the phosphorylation level of Smad2/3, and impaired cell colony forming ability[6].
In vivo, LY364947 (5mg/kg; i.p.; 4 days) enhanced liver regeneration, increased cell proliferation (measured by PCNA, phosphorylated histone 3, p21) levels, recovered of CCl4-metabolizing enzyme CYP2E1 expression in hepatocytes, and improved liver function in a mouse model of acute liver injury induced by carbon tetrachloride (CCL4)[3]. LY364947 (50nM; intravitreal injection; 7 days) almost completely prevented capillary degeneration and retinal vascular damage and slightly attenuated the reduction in number of cells in the ganglion cell layer in a rat model of retinal degeneration induced by N-methyl-D-Aspartate (NMDA)[7].
References:
[1] Peng SB, Yan L, Xia X, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry. 2005;44(7):2293-2304.
[2] Hu X, Zuckerman KS. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res. 2001;10(1):67-74.
[3] Tschernia NP, Gulley JL. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy. BioDrugs. 2022;36(2):153-180.
[4] Karkampouna S, Goumans MJ, Ten Dijke P, Dooley S, Kruithof-de Julio M. Inhibition of TGFβ type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice. Arch Toxicol. 2016;90(2):347-357.
[5] Oka M, Iwata C, Suzuki HI, et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood. 2008;111(9):4571-4579.
[6] Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676-680.
[7] Ueda K, Nakahara T, Mori A, Sakamoto K, Ishii K. Protective effects of TGF-β inhibitors in a rat model of NMDA-induced retinal degeneration. Eur J Pharmacol. 2013;699(1-3):188-193.
LY364947是一种强效的ATP竞争性TGFβR-I抑制剂，其IC50为59nM[1]。TGFβRI是TGF-β通路的I型受体丝氨酸/苏氨酸激酶，激活后磷酸化Smad2/3以介导纤维化、免疫抑制和肿瘤进展[2]。LY364947通过阻断TGF-β/Smad信号通路被广泛用于研究TGF-β相关的纤维化、癌症和免疫调节[3][4]。
在体外，用LY364947（3μM；24小时）处理人皮肤淋巴管微血管内皮细胞（HDLECs）显著诱导Prox1和LYVE-1的表达，并抑制TGF-β1诱导的Smad2磷酸化，同时促进管状结构形成和细胞迁移[5]。用LY364947（10µM；2小时）处理CML白血病起始细胞（LICs）增加了Foxo3a的核外移，降低了Smad2/3的磷酸化水平，并损害了细胞集落形成能力[6]。
在体内，LY364947（5mg/kg；腹腔注射；4天）增强了四氯化碳（CCL4）诱导的急性肝损伤小鼠模型中的肝再生，增加了细胞增殖（通过PCNA、磷酸化组蛋白3、p21测量）水平，恢复了肝细胞中CCL4代谢酶CYP2E1的表达，并改善了肝功能[3]。LY364947（50nM；玻璃体腔注射；7天）几乎完全阻止了N-甲基-D-天冬氨酸（NMDA）诱导的大鼠视网膜退化模型中毛细血管退化和视网膜血管损伤，并轻微减轻了视网膜神经节细胞层细胞数量的减少[7]。
| Cell experiment [1]: | |
Cell lines | human dermal lymphatic microvascular endothelial cells |
Preparation Method | HDLECs were cultured in EGM2-MV medium containing endothelial cell growth supplements with 5% fetal bovine serum. HDLECs were seeded at a density of 2×103 cells/well in 96 well plates, and cells were treated or not with TGF-β (1ng/mL) or LY364947 (3μM). After 24h incubation, Photographs of the cells were taken. Expression of Smad7 and PAI-1 mRNAs was determined by Real-time PCR. Cell numbers were determined by Water-Soluble Tetrazolium (WST) assay. |
Reaction Conditions | 3μM; 24h |
Applications | LY364947 significantly inhibits TGF-β1-induced Smad2 phosphorylation, while promoting cord formation and cell migration. |
| Animal experiment [2]: | |
Animal models | Male Sprague–Dawley rats |
Preparation Method | Male Sprague–Dawley rats weighing 220–240g were maintained in a room with constant temperature (22℃) and constant humidity (55%) under a 12h light/dark cycle with free access to regular rat chow and tap water. The animals were divided into two groups: NMDA+vehicle (dimethyl sulfoxide [DMSO]), NMDA+LY364947. Under general anesthesia with 50mg/kg pentobarbital sodium, 50nM LY364947, or DMSO mixed with 200nM NMDA in a total volume of 5μl was injected into the vitreous cavity of one eye. The same volume of vehicle (5μl) was injected into the vitreous cavity of the other eye as a control. Damage to the inner retinal layers and retinal blood vessels was assessed at 2 and 7 days after the injection. In some animals, the effects of NMDA or NMDA+LY364947 on the pericytes were examined because morphological change of pericytes is a measure of abnormality of blood vessels. |
Dosage form | 50nM; intravitreal injection; 7 days |
Applications | LY364947 almost completely prevented capillary degeneration and retinal vascular damage induced by NMDA. |
References: | |
| Cas No. | 396129-53-6 | SDF | |
| 别名 | HTS466284 | ||
| 化学名 | 4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline | ||
| Canonical SMILES | C1=CC=C2C(=C1)C(=CC=N2)C3=C(NN=C3)C4=CC=CC=N4 | ||
| 分子式 | C17H12N4 | 分子量 | 272.3 |
| 溶解度 | ≥ 24.4mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet